Showing results (291-300 of 306) with videos related to
Sort By:
Pageof 31
Cardiovascular Intervention and Therapeutics|December 19, 2024
Clinical outcome after bleeding events following coronary stenting in patients with and without comorbid peripheral arterial diseaseTineke H Pinxterhuis, Eline H Ploumen, Marlies M Kok, et al.Atherosclerosis|May 31, 2022
Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trialsTineke H Pinxterhuis, Eline H Ploumen, Paolo Zocca, et al.International Journal of Cardiology|December 10, 2022
Risk of bleeding after percutaneous coronary intervention and its impact on further adverse events in clinical trial participants with comorbid peripheral arterial diseaseTineke H Pinxterhuis, Eline H Ploumen, Paolo Zocca, et al.JACC. Cardiovascular Interventions|March 16, 2020
Proximal LAD Treated With Thin-Strut New-Generation Drug-Eluting Stents: A Patient-Level Pooled Analysis of TWENTE I-IIIAriel Roguin, Rosaly A Buiten, Carine J M Doggen, et al.Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|May 22, 2024
Ethnic minorities treated with new-generation drug-eluting coronary stents in two European randomised clinical trialsEline H Ploumen, Edimir Semedo, Carine J M Doggen, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 11, 2021
Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trialEline H Ploumen, Rosaly A Buiten, Paolo Zocca, et al.American Heart Journal|April 15, 2018
Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trialLiefke C van der Heijden, Marlies M Kok, Paolo Zocca, et al.Journal of the American Heart Association|January 12, 2024
Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding RiskRan Kornowski, Maayan Konigstein, Michael Jonas, et al.JACC. Cardiovascular Interventions|May 9, 2020
Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 YearsRosaly A Buiten, Eline H Ploumen, Paolo Zocca, et al.Lancet (London, England)|September 27, 2018
Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trialClemens von Birgelen, Paolo Zocca, Rosaly A Buiten, et al.Pageof 31